Terms: = Lung cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
34 results:
1. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract] [Full Text] [Related]
2. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
[TBL] [Abstract] [Full Text] [Related]
3. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell lung cancer Treated with EGFR Inhibitor.
Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
[TBL] [Abstract] [Full Text] [Related]
4. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
5. Role of Tumor-Infiltrating B Cells in clinical outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.
Brase JC; Walter RFH; Savchenko A; Gusenleitner D; Garrett J; Schimming T; Varaljai R; Castelletti D; Kim J; Dakappagari N; Schultz K; Robert C; Long GV; Nathan PD; Ribas A; Flaherty KT; Karaszewska B; Schachter J; Sucker A; Schmid KW; Zimmer L; Livingstone E; Gasal E; Schadendorf D; Roesch A
Clin Cancer Res; 2021 Aug; 27(16):4500-4510. PubMed ID: 34108180
[TBL] [Abstract] [Full Text] [Related]
6. braf mutations and braf mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M; Preuß C; Roeper J; Metzenmacher M; Eberhardt W; Stropiep U; Wedeken K; Reis H; Herold T; Darwiche K; Aigner C; Stuschke M; Schildhaus HU; Schmid KW; Falk M; Heukamp L; Tiemann M; Griesinger F; Schuler M
Eur J Cancer; 2021 May; 149():211-221. PubMed ID: 33872981
[TBL] [Abstract] [Full Text] [Related]
7. Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study).
Gupta P; Voors AA; Patel P; Lane D; Anker SD; Cleland JGF; Dickstein K; Filippatos G; Lang CC; van Veldhuisen DJ; Metra M; Zannad F; Samani NJ; Jones DJL; Squire IB; Ng LL
Eur J Heart Fail; 2021 Jul; 23(7):1182-1190. PubMed ID: 33759308
[TBL] [Abstract] [Full Text] [Related]
8. ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
Reissig TM; Sara L; Ting S; Reis H; Metzenmacher M; Eberhardt WEE; Zaun G; Herold T; Aigner C; Darwiche K; Stuschke M; Schildhaus HU; Schuler M; Wiesweg M
Lung Cancer; 2020 Nov; 149():10-16. PubMed ID: 32947221
[TBL] [Abstract] [Full Text] [Related]
9. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.
Samà MT; Grosso E; Mele C; Laurora S; Monzeglio O; Marzullo P; Boldorini R; Aluffi Valletti P; Aimaretti G; Scatolini M; Pagano L
Endocrine; 2021 Jan; 71(1):149-157. PubMed ID: 32621051
[TBL] [Abstract] [Full Text] [Related]
10. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcomes of non-small-cell lung cancer patients with braf mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
Bonomo P; Greto D; Desideri I; Loi M; Di Cataldo V; Orlandi E; Iacovelli NA; Becherini C; Visani L; Salvestrini V; Mariotti M; Livi L
Oral Oncol; 2019 Jun; 93():1-7. PubMed ID: 31109688
[TBL] [Abstract] [Full Text] [Related]
13. Treatment of oncogene-driven non-small cell lung cancer.
Kastelijn EA; de Langen AJ; Peters BJM
Curr Opin Pulm Med; 2019 May; 25(3):300-307. PubMed ID: 30865033
[TBL] [Abstract] [Full Text] [Related]
14. Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer.
Wiesweg M; Kasper S; Worm K; Herold T; Reis H; Sara L; Metzenmacher M; Abendroth A; Darwiche K; Aigner C; Wedemeyer HH; Helfritz FA; Stuschke M; Schumacher B; Markus P; Paul A; Rahmann S; Schmid KW; Schuler M
Oncogene; 2019 Apr; 38(16):2953-2966. PubMed ID: 30568222
[TBL] [Abstract] [Full Text] [Related]
15. Distribution of molecular subtypes of advanced lung adenocarcinoma and clinical outcomes in a center of Argentina.
Recondo G; Denninghoff V; Cuello MT; Lorente C; Greco M; De la Vega M; Avagnina A; Recondo G
Medicina (B Aires); 2018; 78(6):385-394. PubMed ID: 30504104
[TBL] [Abstract] [Full Text] [Related]
16. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
Koinis F; Voutsina A; Kalikaki A; Koutsopoulos A; Lagoudaki E; Tsakalaki E; Dermitzaki EK; Kontopodis E; Pallis AG; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2018 Feb; 20(2):140-149. PubMed ID: 28631135
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract] [Full Text] [Related]
18. Tracking the Evolution of Non-Small-Cell lung cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract] [Full Text] [Related]
19. braf and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
[TBL] [Abstract] [Full Text] [Related]
20. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract] [Full Text] [Related]
[Next]